博瑞医药(688166)每日收评(04-07)

Company Overview - The stock of 博瑞医药 (688166) has a comprehensive score of 55.79, indicating a strong performance [1] - The current main cost is 35.78 CNY, with a 5-day main cost of 39.86 CNY and a 20-day main cost of 40.52 CNY [1] Market Activity - In the past year, the stock has not experienced any limit-up or limit-down events [1] - Northbound capital holds 5.9805 million shares, accounting for 1.41% of the circulating shares, with a net purchase of 308,200 shares yesterday [1] Technical Analysis - The short-term resistance level is at 41.49 CNY, while the short-term support level is at 39.67 CNY [2] - If the stock price falls below the short-term support level, a cautious approach is recommended; a breach of the mid-term support level indicates weak buying interest from main funds [2] Fund Flow Data - On April 7, 2025, the net outflow of main funds was 36.2447 million CNY, representing 7% of the total transaction volume [2] - Large orders saw a net outflow of 15.6466 million CNY, while small investors experienced a net inflow of 3.6339 million CNY [2] Related Industry Performance - The chemical pharmaceutical sector has seen a decline of 11.60%, with related concepts such as super fungi down by 10.16% and influenza by 11.00% [2]